Efficacy and cost-effectiveness of clofarabine with high-dose cytarabine for treatment of relapsed/refractory acute myeloid leukemia (R/R AML).

被引：0

作者：

Nunnery, Sara ^{[1
]}

Wang, Dorothy ^{[1
]}

Tan, Marisela ^{[1
]}

Fong, Richard ^{[1
]}

Lo, Mimi Ming ^{[1
]}

Olin, Rebecca L. ^{[1
]}

机构：

[1] Univ Calif San Francisco, San Francisco, CA 94143 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期

关键词：

D O I：

10.1200/JCO.2018.36.15_suppl.e19009

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e19009

引用

页数：2

共 50 条

[21] Infections in relapsed or refractory acute myeloid leukemia patients given clofarabine plus cytarabine
Knoebel, Randall W.
McQuary, Amy
Becker, Pamela
Hendrie, Paul
Petersdorf, Stephen
Appelbaum, Frederick R.
Estey, Eli
LEUKEMIA RESEARCH, 2011, 35 (09) : E164 - E166
[22] Acute hepatotoxicity after high-dose cytarabine for the treatment of relapsed acute myeloid leukemia: a case report
Fu, Samuel
Flannery, Alexander
Bastin, Melissa
PHARMACOTHERAPY, 2017, 37 (12): : E227 - E227
[23] HIGH-DOSE CYTARABINE (HD-ARA-C) IN REFRACTORY AND RELAPSED ADULT ACUTE MYELOGENOUS LEUKEMIA (AML)
HOFELER, H
ANDERS, CU
POPESCU, O
HOFFKEN, K
SCHMIDT, CG
PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1987, 28 : 209 - 209
[24] Sequential conditioning with high dose melphalan followed by busulfan and fludarabine in eldery patients with relapsed or refractory (r/r) acute myeloid leukemia (AML)
Urbahn, M. -A.
Reicherts, C.
Pohlmann, A.
Call, S.
Esseling, E.
Floeth, M.
Marx, J.
Albring, J.
Mikesch, J. -H.
Schliemann, C.
Lenz, G.
Stelljes, M.
BONE MARROW TRANSPLANTATION, 2022, 57 (SUPPL 1) : 101 - 101
[25] Clofarabine plus cytarabine compared to cytarabine alone in older patients with relapsed or refractory (R/R) acute myelogenous leukemia (AML): Results from the phase III CLASSIC 1 trial
Faderl, S.
Wetzler, M.
Rizzieri, D.
Schiller, G. J.
Jagasia, M. H.
Stuart, R. K.
Ganguly, S.
Avigan, D.
Craig, M.
Collins, R.
Maris, M. B.
Kovacsovics, T.
Goldberg, S.
Seiter, K.
Hari, P.
Ravandi, F.
Wang, E. S.
Eckert, S.
Huebner, D.
Kantarjian, H.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[26] High dose cytarabine and cyclophosphamide (hAC) regimen for relapsed or refractory acute myeloid leukemia (AML): a retrospective monocentric analysis
Fix, P.
Fricke, H-J
Spies-Weisshart, B.
La Rosee, P.
Hochhaus, A.
Scholl, S.
ONKOLOGIE, 2010, 33 : 138 - 139
[27] Chemomodulation of sequential high-dose cytarabine by fludarabine in relapsed or refractory acute myeloid leukemia: a randomized trial of the AMLCG
M Fiegl
M Unterhalt
W Kern
J Braess
K Spiekermann
P Staib
A Grüneisen
B Wörmann
D Schöndube
H Serve
A Reichle
M Hentrich
X Schiel
C Sauerland
A Heinecke
C Rieger
D Beelen
W E Berdel
T Büchner
W Hiddemann
Leukemia, 2014, 28 : 1001 - 1007
[28] Safety and activity of venetoclax in combination with high-dose cytarabine in children with relapsed or refractory acute myeloid leukemia.
Karol, Seth E.
Alexander, Thomas
Das Gupta, Soumyasri
Pounds, Stanley B.
Canavera, Kristin
Klco, Jeffery M.
Lacayo, Norman James
Pui, Ching-Hon
Opferman, Joseph T.
Rubnitz, Jeffrey E.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[29] Chemomodulation of sequential high-dose cytarabine by fludarabine in relapsed or refractory acute myeloid leukemia: a randomized trial of the AMLCG
Fiegl, M.
Unterhalt, M.
Kern, W.
Braess, J.
Spiekermann, K.
Staib, P.
Grueneisen, A.
Woermann, B.
Schoendube, D.
Serve, H.
Reichle, A.
Hentrich, M.
Schiel, X.
Sauerland, C.
Heinecke, A.
Rieger, C.
Beelen, D.
Berdel, W. E.
Buechner, T.
Hiddemann, W.
LEUKEMIA, 2014, 28 (05) : 1001 - 1007
[30] Cost-Effectiveness Analysis of Gilteritinib Versus Salvage Chemotherapy (SC) for the Treatment of Relapsed or Refractory (R/R) FLT3-Mutated (FLT3mut+) Acute Myeloid Leukemia (AML)
Zeidan, Amer M.
Qi, Cynthia Z.
Pandya, Bhavik J.
Garnham, Andy
Yang, Hongbo
Shah, Manasee V.
BLOOD, 2019, 134

← 1 2 3 4 5 →